HEALTH

Axium to distribute Elaprase

BY Alaric DeArment

LAKE MARY, Fla. Specialty pharmacy provider Axium Healthcare Pharmacy will serve as a limited distribution provider for a drug to treat a serious genetic disorder, Axium said Monday.

Axium will distribute Shire Human Genetic Therapies’ Elaprase (idursulfase), used to treat Hunter syndrome, also known as mucopolysaccharidosis II. According to the Mayo Clinic, Hunter syndrome causes chains of sugar molecules to build up in the body over time, resulting in mental deficiency and retardation, deformities, deafness and other symptoms. The juvenile-onset form of the disease typically results in death in the early teens to early 20s, while those with the late-onset form live for 20 to 60 years. It mostly affects boys.

“Axium is pleased to be granted the opportunity to be a provider of Elaprase in Puerto Rico,” Axium president and CEO Mark Montgomery said. “This selection continues to build momentum on Axium’s strong clinical programs and our investment in providing solutions for our clients.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Nearly $3 million for TB research awarded under FDA’s Critical Path Initiative

BY Alaric DeArment

SILVER SPRING, Md. The Food and Drug Administration has awarded almost $3 million for tuberculosis research, the agency said Monday.

The FDA said it awarded $2.9 million to six research products to help with the diagnosis, treatment and prevention of TB under its Critical Path Initiative. The disease has seen increasing prevalence around the world, and two recent articles by the agency’s Office of Critical Path programs noted that advances are needed to shorten therapy and treat drug-resistant forms of the disease.

The Critical Path Initiative was created in 2004 to drive innovation in the development, evaluation and manufacturing of medical products.

“FDA recognized an urgent need for the engagement and leadership of public health institutions to promote this critical, but neglected, area of medical therapeutics,” FDA commissioner Margaret Hamburg said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Advil makers encourage safe medication disposal

BY Michael Johnsen

MADISON, N.J. Pfizer Consumer Healthcare on Monday launched a consumer campaign encouraging Americans to clean out their medicine cabinets and properly dispose of unwanted, expired and recalled products.

Pfizer also is partnering with Suzy Cohen, author of “The 24-Hour Pharmacist,” to offer essential tips on medicine cabinet safety. “This campaign encourages people to take a few simple steps to help ensure the safety of everyone in their household,” Cohen said. “We all need to declutter and clean out our medicine cabinets.”

 

Arecent poll found that nearly half of Americans do not always look at the expiration date on over-the-counter medications before taking them, Pfizer noted. And to encourage consumers to do exactly that, Pfizer is providing a coupon for a free bottle of Advil to the first 500,000 eligible people who register.

 

 

Pfizer also is encouraging consumers to properly dispose of medicines, suggesting that when disposing of unwanted, expired or recalled products in the medicine cabinet, consumers should take precautions to ensure they protect children, pets and the environment from potentially negative effects. For example, no medicine should be disposed of by pouring into a sink, toilet or storm drain. The campaign directs consumers to consult their pharmacists on proper disposal practices, or to visit FDA.gov and search for “disposal.”

 

 

For consumers who wish to register for one of the 500,000 free bottles of Advil, Pfizer has established the website MedicineCabinetSafety.com.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?